The information regarding this transaction is sourced from an SEC filing published on May 8, 2025, through the SEC EDGAR system. While the specific form type is not identified in the available data, the filing confirms the announced status of the asset sale. No expected closing date or other timeline milestones have been disclosed.
Accelerate Diagnostics retained three advisors to represent its interests in the transaction. Fried, Frank, Harris, Shriver & Jacobson LLP serves as legal counsel to the target. On the financial advisory side, Solic Capital is serving as financial advisor, while Perella Weinberg Partners L.P. is acting as restructuring investment banker. No advisors representing the acquirer or other parties to the transaction have been identified in the available source materials.
No separate legal advisors beyond Fried, Frank, Harris, Shriver & Jacobson LLP have been disclosed. The legal representation appears to be consolidated under the single counsel identified for Accelerate Diagnostics.
The transaction involves an asset sale of Accelerate Diagnostics' assets as part of a bankruptcy process, valued at $36,900,000. Beyond the aggregate disclosed value, no further detail regarding the consideration structure, whether cash or stock or mixed, has been provided. The specific identity of the acquirer or purchaser of the assets has not been disclosed in the available materials.
Notable gaps in the public disclosure include the identity of the acquiring party, the expected closing date, the composition of the consideration (cash, stock, other instruments, or a combination thereof), any details regarding which specific assets are being sold, the terms of the bankruptcy sale process, and any additional conditions or milestones that may apply to the transaction. No information regarding potential financing or any debt arrangements related to the asset sale has been provided.